Does Fallon Community Health Plan (FCHP) Cover Eliquis?

What Is Eliquis and Why Is It Prescribed?

Eliquis (apixaban) is an oral, direct Factor Xa inhibitor approved by the FDA in 2012 to reduce stroke risk in non-valvular atrial fibrillation (AFib) and in 2014 for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. It is also indicated for post-surgical VTE prophylaxis after hip or knee replacement [2]. Prescribers choose it because large randomized controlled trials showed a favorable balance of efficacy and bleeding risk compared with warfarin and other anticoagulants.

Mechanism of Action

Apixaban selectively inhibits free and clot-bound Factor Xa, interrupting the coagulation cascade before thrombin generation without requiring antithrombin as a cofactor [3]. This mechanism produces predictable pharmacokinetics, which means routine INR monitoring is not required, a practical advantage over warfarin for most patients [4].

FDA-Approved Indications

• Stroke and systemic embolism prevention in non-valvular AFib
• Treatment of DVT and PE
• Reduction in risk of recurrent DVT and PE after initial therapy
• Prophylaxis of DVT after hip or knee replacement surgery [1]

The American Heart Association and American College of Cardiology 2023 AFib guidelines recommend direct oral anticoagulants (DOACs) such as apixaban over warfarin in eligible patients, citing superior safety profiles in clinical trial data [5].

Key Clinical Evidence

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with warfarin in patients with AFib. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs. 1.60% per year; hazard ratio 0.79, 95% CI 0.66-0.95; P<0.001 for non-inferiority and P=0.01 for superiority) [6]. Major bleeding occurred in 2.13% per year with apixaban versus 3.09% per year with warfarin (P<0.001) [6]. That single trial enrolled more patients than most anticoagulation studies and is frequently cited by payers when reviewing coverage criteria.

The AMPLIFY trial (N=5,395) demonstrated that apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily was non-inferior to conventional therapy (low-molecular-weight heparin plus warfarin) for treating acute VTE, with significantly less major bleeding (0.6% vs. 1.8%; relative risk 0.31; P<0.001) [7].

How FCHP Formularies Work

FCHP operates several plan types: commercial HMO/PPO products, Medicare Advantage plans, and MassHealth-managed Medicaid products. Each plan maintains a separate formulary, so coverage for Eliquis can differ based on which product a member holds.

Tiers and Cost Sharing

FCHP uses a multi-tier formulary structure. Generic drugs sit on Tier 1 or Tier 2 with the lowest copays. Brand-name drugs with no generic equivalent typically land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which carry higher cost sharing. Because no FDA-approved generic apixaban existed as of early 2025, Eliquis is placed in the brand-name tiers [8].

Tier placement matters because a Tier 3 drug on a typical FCHP commercial plan might carry a $50-$60 monthly copay, while a Tier 4 placement can mean 25-40% coinsurance, potentially several hundred dollars per fill for a 30-day supply.

Prior Authorization Requirements

FCHP, like most Massachusetts commercial and Medicare Advantage insurers, often attaches prior authorization (PA) requirements to Eliquis. Common PA criteria include:

• A confirmed diagnosis (e.g., documented paroxysmal, persistent, or permanent non-valvular AFib on ECG or Holter monitoring)
• Documentation that warfarin was tried and resulted in subtherapeutic or supratherapeutic INR control, or that a contraindication exists
• Prescriber attestation of a CHA2DS2-VASc score at or above the threshold recommended by guidelines (2 or higher in males, 3 or higher in females, per 2023 ACC/AHA guidance) [5]
• For VTE treatment, imaging confirmation (duplex ultrasound or CT pulmonary angiography)

The FDA label for apixaban specifies approved dosing and indications, and payers reference it when evaluating medical necessity [1].

Medicare Advantage Formularies

FCHP Medicare Advantage plans follow CMS Part D formulary requirements. Under CMS rules, plans must include at least two drugs in each therapeutic category. The direct oral anticoagulant class typically has apixaban, rivaroxaban, and dabigatran available, though tier placement varies by plan year [9]. Members should check the specific Evidence of Coverage document for their plan year because formulary tiers can change annually. CMS publishes the Medicare Plan Finder tool where members can search apixaban by plan name [9].

During the 2025 plan year, the Inflation Reduction Act's $2,000 out-of-pocket cap for Medicare Part D enrollees became effective, which limits maximum annual spending on covered Part D drugs including Eliquis [10].

Checking Your Specific FCHP Coverage

Step-by-Step Verification

1. Log in to the FCHP member portal at fchp.org and manage to the formulary or drug search tool.
2. Enter "apixaban" or "Eliquis" and select your plan name.
3. Note the tier, any PA requirements, and whether step therapy applies.
4. Call the pharmacy benefit phone number on the back of your FCHP insurance card if the online tool is unclear.
5. Ask your prescribing physician or their office staff to submit a PA request with supporting clinical documentation before the first fill.

Formulary searches on the FCHP portal reflect the current plan year. If your plan renews in January, check again in November or December during open enrollment.

What to Bring to the Pharmacist

When picking up Eliquis for the first time, bring the FCHP insurance card, a government-issued ID, and confirmation of any PA approval number if one was required. If the pharmacy's system shows a coverage rejection, ask for a 72-hour emergency supply (pharmacists in Massachusetts may dispense a short-term supply under state pharmacy regulations) while the PA is being processed.

Reading the Explanation of Benefits

After filling Eliquis, FCHP sends an Explanation of Benefits (EOB) showing the drug's submitted price, plan payment, and member cost share. Reviewing this document helps confirm whether the PA was applied correctly and whether any cost-sharing assistance was credited.

Prior Authorization: The Complete Process

Prior authorization for Eliquis under FCHP is not an automatic denial. It is a documentation review that most patients with documented AFib or VTE can pass when their provider submits the right records.

What the Prescriber Submits

The prescribing cardiologist or internist typically submits a PA request through FCHP's electronic prior authorization portal or via fax. Required documents generally include:

• Office visit notes confirming the diagnosis
• Relevant cardiac monitoring results (ECG strip showing AFib or Holter report)
• INR history if warfarin was previously used (showing poor control, defined as time-in-therapeutic-range below 65-70%, consistent with ARISTOTLE enrollment criteria [6])
• Documentation of any contraindication to warfarin (e.g., history of intracranial hemorrhage, pregnancy planning, drug interactions)

Timelines and Approvals

Under Massachusetts state insurance regulations and federal guidelines, non-urgent PA requests must receive a decision within 3 business days; urgent requests require 24-hour turnaround. FCHP's medical management team reviews the clinical file against their coverage criteria and issues an approval, denial, or request for additional information.

Approval is valid for a defined period, commonly 12 months, after which a renewal PA may be required.

If the PA Is Denied

A denial does not mean permanent loss of coverage. FCHP members have the right to a formal appeal. The appeal process includes:

1. Internal appeal reviewed by a board-certified physician in the relevant specialty.
2. External Independent Medical Review through the Massachusetts Office of Patient Protection if the internal appeal is upheld.

Nationally, data from the Kaiser Family Foundation show that insurer-level appeals are granted in roughly 39-59% of cases when the member or provider submits additional clinical evidence [11]. Providing published guideline recommendations, such as the ACC/AHA 2023 AFib guideline statement recommending DOACs over warfarin [5], can strengthen an appeal.

Cost and Financial Assistance Options

Manufacturer Copay Card

Bristol-Myers Squibb and Pfizer offer a copay savings program for commercially insured patients who are not enrolled in a federal or state government health insurance program (Medicare, Medicaid, CHIP, or VA). Eligible patients may pay as little as $10 per 30-day fill [12]. This program does not apply to FCHP Medicare Advantage members.

Patient Assistance Program

For uninsured or underinsured patients, Bristol-Myers Squibb's Together on Diabetes and cardiovascular patient assistance programs provide Eliquis at no cost to qualifying patients based on income thresholds [12]. Even patients with insurance but high cost sharing may qualify if their out-of-pocket burden exceeds program limits.

State Pharmaceutical Assistance

Massachusetts does not have a general state pharmaceutical assistance program equivalent to some other states, but MassHealth (Medicaid) covers Eliquis for eligible members under its pharmacy benefit, with cost sharing typically at $0-$3.65 per fill for most MassHealth members under current state regulations [13].

Comparing Total Annual Cost

At Tier 4 with 25% coinsurance on a $600/month drug, a commercially insured FCHP member without assistance could owe $1,800 per year. With the BMS/Pfizer copay card capped at $10 per fill, the same member pays $120 per year. Running this comparison with the plan's formulary and the manufacturer's current card terms before the first fill can save over $1,600 annually.

Clinical Rationale for Choosing Apixaban Over Other Anticoagulants

Prescribers and payers both assess whether apixaban is the most appropriate anticoagulant for a given patient, especially when step therapy requires a warfarin trial first. The clinical literature provides concrete comparisons.

Apixaban vs. Warfarin

ARISTOTLE (N=18,201) is the definitive head-to-head study [6]. Beyond the headline efficacy results, apixaban produced a 31% relative reduction in major bleeding and a 58% relative reduction in hemorrhagic stroke. For patients with labile INR on warfarin (time in therapeutic range below 65%), the net clinical benefit of switching to apixaban is particularly pronounced, as the FDA label notes [1].

Apixaban vs. Rivaroxaban

No large head-to-head randomized trial has directly compared apixaban and rivaroxaban in AFib. Observational data from the ARISTOPHANES study (N=321,081 Medicare beneficiaries) found that apixaban was associated with lower rates of stroke or systemic embolism and major bleeding compared with rivaroxaban, though residual confounding limits causal inference [14]. FCHP may list rivaroxaban as a preferred DOAC on some formularies due to cost or contract arrangements, making it the step-therapy agent before apixaban.

Apixaban vs. Dabigatran

The RE-LY trial (N=18,113) established dabigatran's efficacy in AFib [15]. Apixaban and dabigatran are not directly compared in an adequately powered RCT, but a 2022 network meta-analysis in The Lancet (N=254,464 patient-years pooled across 23 trials) found apixaban had the most favorable bleeding profile among DOACs while maintaining non-inferior stroke prevention [16].

When Warfarin Remains Appropriate

Warfarin remains the anticoagulant of choice in mechanical heart valve patients and moderate-to-severe mitral stenosis. The RE-ALIGN trial stopped early because dabigatran caused more thromboembolic and bleeding events than warfarin in mechanical valve patients [17]. Apixaban has no completed large-scale RCT in mechanical valves, and the FDA label contraindicates its use in that setting [1]. FCHP PA criteria will typically not require a warfarin trial for patients with documented warfarin contraindication in these specific settings.

Special Populations and Dosing Considerations

Dose Reduction Criteria

The standard AFib dose is 5 mg twice daily. Dose reduction to 2.5 mg twice daily applies when the patient meets at least two of the following three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [1]. The FDA label describes this as the "2-of-3 rule" and it is widely reproduced in prescribing references [3].

Getting the dose right matters for PA accuracy. A PA submitted for 5 mg twice daily in an 83-year-old weighing 52 kg with a creatinine of 1.7 mg/dL may trigger a clinical review because the 2.5 mg dose is indicated. Mismatched dosing is a common reason PAs require additional documentation.

Renal Impairment

Apixaban does not require dose adjustment for mild or moderate renal impairment beyond the 2-of-3 rule. For patients with end-stage renal disease on dialysis, the 2023 ACC/AHA AFib guideline notes that apixaban may be used with caution, citing observational data showing acceptable outcomes, though the evidence is less strong than in patients with preserved renal function [5]. The FDA label does not specifically approve apixaban in dialysis patients [1].

Older Adults

Older adults (age 75 and above) represent a substantial portion of AFib patients. A subgroup analysis of ARISTOTLE showed that the relative benefit of apixaban over warfarin was preserved in patients aged 75 and older, with major bleeding rates of 3.33% per year with apixaban versus 4.67% per year with warfarin in that subgroup [6].

What to Do If FCHP Will Not Cover Eliquis

File a Formulary Exception

A formulary exception asks FCHP to cover a non-formulary or restricted drug outside normal step-therapy rules. The prescriber submits a written clinical justification explaining why formulary alternatives are medically inappropriate for this specific patient. Common justifications include:

• Prior major bleeding on warfarin
• Drug interaction (e.g., rifampin, which significantly reduces warfarin efficacy and also reduces apixaban exposure per FDA labeling [1])
• Demonstrated INR instability on warfarin despite adherence
• Patient preference with documented counseling is generally not sufficient alone, but combined with clinical factors it can support an exception

Seek an Independent Medical Review

Massachusetts law entitles members to an external independent medical review (IMR) of any denied PA or formulary exception for a drug their provider believes is medically necessary. The Massachusetts Office of Patient Protection handles these reviews. External review outcomes are binding on the health plan.

Switch to a Plan That Lists Eliquis as Preferred

During open enrollment, check whether a different FCHP plan tier or a competing Massachusetts insurer lists apixaban at a lower formulary tier. The Massachusetts Health Connector allows side-by-side plan comparisons at mahealthconnector.org.

Ask About 90-Day Supply

If coverage is approved, a 90-day mail-order supply often carries a lower total copay than three separate 30-day fills. FCHP's pharmacy benefit manager typically offers a mail-order pharmacy option. For a Tier 3 drug with a $50 monthly copay, a 90-day mail-order supply might cost $100-$125, saving $25-$50 per quarter.